Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study

Isshi, Kimio; Matsuhashi, Nobuyuki; Joh, Takashi; Higuchi, Kazuhide; Iwakiri, Katsuhiko; Kamiya, Toshio; Manabe, Noriaki; Ogawa, Maiko; Arihiro, Seiji; Haruma, Ken; Nakada, Koji

doi:10.1007/s00535-019-01546-0

Cited by 8 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The co‐existence of FD has been reported to be common in GERD patients, with an incidence between 9–63.8% 17,32–35 . FD symptoms also affect various aspects of daily life, reducing the patient's QOL, 23–26 and it has been reported that the co‐existence of FD and GERD symptoms caused a greater decrease in the patients' QOL than GERD symptoms alone 18 .…”

Section: Discussionmentioning

confidence: 99%

“…[9][10][11][12][13] The co-existence of FD has been reported to be common in GERD patients, with an incidence between 9-63.8%. 17,[32][33][34][35] FD symptoms also affect various aspects of daily life, reducing the patient's QOL, [23][24][25][26] and it has been reported that the coexistence of FD and GERD symptoms caused a greater decrease in the patients' QOL than GERD symptoms alone. 18 However, the magnitude and characteristics of the effects of co-existing GERD and FD symptoms on each item that represents the various aspects of daily life have not yet been clarified.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and Aim Patients with gastroesophageal reflux disease (GERD) frequently also have functional dyspepsia (FD) symptoms, which impair their quality of life. However, the magnitude and characteristics of the effects of each symptom on daily life have been unclarified. Using multiple regression analysis, we aimed to clarify these questions. Methods We enrolled 290 patients from 29 institutions across Japan, in this prospective, observational study. Patients responded to three questionnaires (Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test [GERD‐TEST], Hospital Anxiety and Depression Scale [HADS], and 8‐item Short‐Form Health Survey [SF‐8]) before and after 4 weeks of proton pump inhibitor treatment. Pearson correlation and multiple regression analyses were conducted between symptoms such as typical GERD, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) of FD, and aspects of daily life, namely, level of satisfaction with the daily life of GERD‐TEST, anxiety and depression score of HADS, and physical and mental component summary of SF‐8. Results Pearson correlation analysis showed a significant correlation in all combinations between GERD/FD‐EPS/FD‐PDS symptoms and the nine aspects of daily life. However, multiple regression analysis results deviated from these results, with the most significant effects seen in the PDS‐symptom subscale (SS) on the five aspects of daily life, that is, dissatisfaction with eating, daily life‐SS, anxiety, depression, and mental component summary (MCS) whereas the significant effects in GERD‐SS on five aspects of daily life, that is, dissatisfaction for eating, anxiety, depression, physical component summary, and MCS, disappeared. Conclusion Dealing with co‐existing FD symptoms without overlooking them may be important in the management of GERD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Unhealthy eating habits and incorrect lifestyles might be also considered independent predictors of gastrointestinal health (Saneei, Esmaillzadeh, Keshteli, et al, 2020). Other overlapping gastrointestinal disorders are usually present in these subjects (Isshi et al, 2019). Gastroesophageal reflux is commonly associated with GD causing significant negative consequences in the QoL (Wei, Hsueh, Wen, Chen, & Wang, 2019).…”

Section: Discussionmentioning

confidence: 99%

A standardized extract ofOpuntia ficus‐indica(L.) Mill andOlea europaeaL. improves gastrointestinal discomfort: Adouble‐blinded randomized‐controlledstudy

Malfa

Giacomo

Cardia

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

Gastrointestinal discomfort (GD), which often includes gastroesophageal reflux disease (GERD), is a common disorder in healthy adults affecting 40% of the worldwide population. The symptoms related to GD can have a negative impact on the quality of life (QoL). Current treatments for GERD are associated with side effects. We conducted a randomized double-blind placebo-controlled trial to assess the effect of a standardized extract of Opuntia ficus-indica L. cladodes and Olea europaea L. leaves on the symptoms and QoL of healthy adults with GD. One hundred healthy participants with GD were enrolled in the study and divided into two groups: 60 participants taking verum (400 mg/day) and 40 taking the placebo for 8 weeks. The Gastrointestinal Quality of Life index (GIQLI) and GERD Symptom Assessment Scale (GSAS) questionnaires were administered at the beginning of the study and after 4 and 8 weeks.The group treated with verum experienced a statistically significant improvement of GIQLI and GSAS scores (p < .001). Moreover, the effect size measured revealed a clinical significance. A day-dependent improvement of symptoms was also observed.The standardized extract represents a fast, effective, and well-tolerated treatment for improving symptoms related to GD and GERD.

show abstract

“…Symptom severity was assessed and quantified before and after 4 weeks of treatment using the Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test (GERD-TEST). Depending on the result obtained, the patients were divided into two groups [ 41 , 42 ] ( Figure 1 ). Informed consent, both written and oral, was obtained from each participant first entering the follow-up phase.…”

Section: Methodsmentioning

confidence: 99%

Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett’s Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens

Crispino

Ciarambino

Giordano

2023

CIMB

View full text Add to dashboard Cite

Barrett’s esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malignant transformation. The aim of the present study was to evaluate the variation of FAS, p53, and Ki67 expressions in two groups of 21 BE patients each, after one year of continuous (group A) or discontinuous (group B) treatment with esomeprazole 40 mg/day in comparison to the initial expression. In both the two groups of BE patients, biopsies were taken from pathologic sites of the mucosa for histological and immuno-histochemical detection of FAS, Ki67, and p53 at entry and after one year of Esomeprazole 40 mg treatment. FAS expression was positive when a strong granular cytoplasmic staining was observed in esophageal cells. Ki67 and p53 were defined as positive when nuclear staining was clearly detected at ×10 magnification. FAS expression was reduced in 43% of patients treated with Esomeprazole continuously in comparison to the 10% of patients treated with Esomeprazole on demand (p = 0.002). Ki67 expression was reduced in 28% of continuously treated patients in comparison to 5% of patients treated on demand (p = 0.001). The p53 expression decreased in 19% of continuously treated patients in comparison to an increase in 2 patients (9%) treated on demand (p = 0.05). Continuously Esomeprazole treatment could help in the diminution of metabolic and proliferative activities in the esophageal columnar epithelium and in part it can help prevent the oxidative damage against cellular DNA, resulting in a diminution in p53 expression.

show abstract

Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study

Cited by 8 publications

References 22 publications

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

Comparison of the effects of individual symptoms of gastroesophageal reflux disease co‐existing functional dyspepsia on patients' daily lives: A prospective, observational study

A standardized extract ofOpuntia ficus‐indica(L.) Mill andOlea europaeaL. improves gastrointestinal discomfort: Adouble‐blinded randomized‐controlledstudy

Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett’s Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens

Contact Info

Product

Resources

About